Karyopharm Therapeutics (KPTI) Reiterated at Overweight by Cantor Fitzgerald Mar 6, 2026 06:54AM
Karyopharm Therapeutics (KPTI) March 10 calls active, share price up 32% Feb 12, 2026 02:23PM
Karyopharm Therapeutics (KPTI) Misses Q4 EPS by 571c Feb 12, 2026 07:45AM
Cantor Fitzgerald Starts Karyopharm Therapeutics (KPTI) at Overweight Feb 5, 2026 12:36AM
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note Dec 22, 2025 07:06AM


Dec 21, 2025 04:00AM Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
Dec 17, 2025 07:01AM Piper Sandler Highlights Karyopharm Therapeutics (KPTI) As a 2026 Top Pick
Nov 5, 2025 03:43PM RBC on Karyopharm Therapeutics (KPTI): 'we believe the reward/risk profile in shares...remains very attractive'
Nov 3, 2025 04:20PM Karyopharm Therapeutics (KPTI) files for 2.81M share offering by selling stockholders
Nov 3, 2025 04:16PM Karyopharm Therapeutics (KPTI) files for 9.57M share offering by selling stockholders
Oct 13, 2025 06:38AM H.C. Wainwright Upgrades Karyopharm Therapeutics (KPTI) to Buy
Oct 9, 2025 08:42AM Karyopharm Therapeutics (KPTI) PT Lowered at Piper Sandler Amid Financial Restructuring
Oct 8, 2025 03:17PM Karyopharm Therapeutics (KPTI) PT Lowered to $6 at Leerink Partners
Aug 11, 2025 10:59AM Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 432c
Jul 16, 2025 06:44AM H.C. Wainwright Downgrades Karyopharm Therapeutics (KPTI) to Neutral
Jul 11, 2025 07:33AM Karyopharm Therapeutics (KPTI) is further reducing its workforce by approximately 20%
May 13, 2025 09:44AM Karyopharm Therapeutics (KPTI) PT Lowered to $33 at RBC Capital
May 13, 2025 07:24AM Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 251c
Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets
Mar 19, 2025 10:02AM Piper Sandler: 'Own Karyopharm Therapeutics (KPTI) for Myelofibrosis Data in 2H:25'; PT Split-Adjusted
Feb 24, 2025 08:41AM Karyopharm Therapeutics (KPTI) Announces 1:15 Reverse Share Split
Feb 20, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Karyopharm Therapeutics (KPTI)
Feb 19, 2025 07:33AM Karyopharm Therapeutics (KPTI) Tops Q4 EPS by 1c ; Offers Guidance
Jan 30, 2025 05:26PM Karyopharm increases authorized shares, approves reverse split
Jan 15, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Karyopharm Therapeutics (KPTI)
Jan 2, 2025 07:02AM Karyopharm Therapeutics (KPTI) Appoints Lori Macomber as CFO
Nov 20, 2024 04:06PM Karyopharm Therapeutics (KPTI) Appoints Kristin Abate as Chief Accounting Officer
Nov 6, 2024 07:57AM Karyopharm Therapeutics (KPTI) PT Raised to $5 at Piper Sandler
Nov 5, 2024 07:34AM Karyopharm Therapeutics (KPTI) Reports In-Line Q3 EPS ; Offers Guidance
Oct 31, 2024 07:31AM Karyopharm Therapeutics (KPTI) Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Aug 6, 2024 07:34AM Karyopharm Therapeutics (KPTI) Tops Q2 EPS by 11c ; Offers Guidance
Jul 1, 2024 06:35AM Karyopharm Therapeutics (KPTI) PT Lowered to $7 at H.C. Wainwright
Jun 10, 2024 05:39AM RBC Capital Reiterates Outperform Rating on Karyopharm Therapeutics (KPTI)